BG
VRDN icon

Bellevue Group’s Viridian Therapeutics VRDN Stock Holding History

Bellevue Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$132M Buy
6,726,144
+2,367,617
+54% +$70.3M 3.13% 9
2025
Q4 		$136M Buy
+4,358,527
New +$120M 2.57% 13
2024
Q2 		– Sell
-19,100
Closed -$334K – 177
2024
Q1 		$334K Sell
19,100
-10,900
-36% -$211K 0.01% 144
2023
Q4 		$653K Sell
30,000
-33,770
-53% -$533K 0.01% 129
2023
Q3 		$978K Buy
63,770
+19,370
+44% +$370K 0.02% 129
2023
Q2 		$1.06M Sell
44,400
-1,700
-4% -$43.6K 0.02% 129
2023
Q1 		$1.17M Hold
46,100
– – 0.02% 125
2022
Q4 		$1.35M Hold
46,100
– – 0.02% 133
2022
Q3 		$946K Sell
46,100
-2,900
-6% -$52.1K 0.01% 138
2022
Q2 		$567K Buy
+49,000
New +$659K 0.01% 147

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return